Hassan Hamade, MD

Hassan Hamade, MD, of the Icahn School of Medicine at Mount Sinai, spoke about some of the most notable takeaways on deucravacitinib for 

 from an HCPLive Clinical Forum on plaque psoriasis.

, Hamade discussed the clinical considerations related to the use of deucravacitinib in psoriasis management. He also highlighted his views on deucravacitinib and experiences managing inflammatory skin conditions. In this segment of his interview, Hamade was asked whether the group’s findings changed his approach to shared decision-making.

Impact of Consensus Panel Findings on Deucravacitinib for Psoriasis, with Hassan Hamade, MD

“[In] people who are afraid of needles…you could argue that eventually they'll get over it, which I've seen maybe 5600 times,” Hamade said. “There are patients, however, who've reached a point where their psoriatic arthritis has reached debilitation of their joints and of their hands…For those patients, I want to be able to [say], ‘I can give you an injection unless you have somebody at home to do it for you.’ This will be quite hard, so I'd rather give you a pill that I know will benefit you.”

In terms of safety, tolerability, or long-term data, Hamade was asked if anything at the forum increased his confidence or raised new questions about implementing deucravacitinib.

“It was very it was actually awesome that they re-emphasized the longer-term safety data that's been coming out, which was not unexpected, but always good to see with these oral ‘JAKS’, it's very good to see,” Hamade said. “I think for dermatologists in particular, more so than rheumatologists or primary care, safety tests are huge, because we have so many options, especially topical options, that are effective enough and safe biologics. So re-emphasizing that was awesome…Things like CPK elevations that weren't necessarily clinically significant and the consistent yet low rate of thromboembolic events, which makes us comfortable prescribing these things.”

For any further information on deucravacitinib and its utilization in patients with inflammatory conditions such as psoriasis, view Hamade’s full vide segment posted above.

The quotes contained in this summary were edited for the purposes of clarity.

Hamade H. Insights on Deucravacitinib for Psoriasis During Expert Consensus Panel, with Hassan Hamade, MD. HCPLive. July 17, 2025. 

https://www.hcplive.com/view/insights-deucravacitinib-psoriasis-during-expert-consensus-panel-hassan-hamade-md

Videos

In this interview segment, Hamade highlights the potential benefits of an oral drug like deucravacitinib in psoriasis and psoriatic arthritis.

Impact of Findings on Deucravacitinib for Psoriasis, with Hassan Hamade, MD

Few areas in dermatology have experienced the rate of advancement as plaque psoriasis in recent years, which further emphasizes the need for reliable education for specialists and general providers. Earlier this year, HCPLive hosted led by Andrew Alexis, MD, MPH, a clincial forum titled "Optimizing Treatment Strategies for Moderate-to-Severe Plaque Psoriasis: Addressing High-Impact Areas and Recalcitrant Disease".  

, were also discussed by one of the attendees: Hassan Hamade, MD, from the Icahn School of Medicine at Mount Sinai.

 about the clinical forum, highlighting what the findings impacted as far as his own thinking about plaque psoriasis and the role of deucravacitinib.

Insights on Deucravacitinib for Psoriasis During Expert Consensus Panel, with Hassan Hamade, MD

“More than anything, it was the re-emphasis on who would benefit from a small molecule inhibitor,” Hamade explained. “Of course, it doesn't hurt to emphasize that the safety profile is fantastic and that there will be many patients where this is not only a great standalone but also a great adjunct. I think, more than anything, the reminder of it being used as an adjunct for patients with incomplete therapy is great. You have patients on regular biologics, and if you need to give them that extra ‘oomph,’ this is a very safe way to do so, with clear efficacy and clear safety boundaries.”

Hamade was also asked if any of the real-world evidence or patient-reported outcomes around deucravacitinib resonated with his own experience managing psoriasis.

“The patient report outcomes are consistent with what we saw between trials and my own patients,” Hamade said. “We definitely see patients who are fairly happy with the medication, with their quality of life improving in many different outcomes. Even if we like trials to look at very hard metrics, there are softer metrics that are just as important to patients' quality of life. These really stand out with how the patients were feeling. Pills are always easier than an injection, and that's what you're doing with deucravacitinib. Beyond that, patients will tell you they have less itch, less pain, and they're sleeping better. These are all things that are not primary endpoints, but are fundamental to the patient experience and their overall well-being.”

For any additional information on deucravacitinib’s use in psoriasis, view the full interview segment with Hamade posted above.

The quotes contained in this summary were edited for clarity.

Shah M, Burshtein J, Lebwohl M, et al. A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus Panel. J Drugs Dermatol. 2025 Feb 1;24(2):147-155. 

Shah M. Efficacy, Safety of Deucravacitinib for Psoriasis, with Milaan Shah, MD. HCPLive. June 13, 2025. Accessed July 16, 2025. 

https://www.hcplive.com/view/efficacy-safety-deucravacitinib-psoriasis-milaan-shah-md

This interview with Hamade highlights some of the most notable takeaways regarding deucravacitinib’s safety among patients with psoriasis.

Hassan Hamade, MD

Articles